Patents Examined by James D. Anderson
  • Patent number: 10688070
    Abstract: A preparation for treatment and/or prevention of seizures comprising a non-mammalian derived mixture of serine glycerophospholipids (PS) conjugates, wherein the mixture comprises (a) Eicosapentaenoic acid (EPA) conjugated to PS and (b) Docosahexaenoic acid (DHA) conjugated to PS, and methods of treatment of seizures with same.
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: June 23, 2020
    Assignee: ENZYMOTEC LTD.
    Inventors: Daphna Zaaroor Regev, Yael Herzog, Robert Chudnow, Yael Richter, Gali Olga Soria Artzi
  • Patent number: 10682360
    Abstract: Described herein are new approaches to antimicrobial therapy, which includes the development of new combinations of antibiotic agents as well as their use for specific therapeutic purposes. These specific therapeutic purposes may apply to clinical situations inherently different from treatment of infections that require systemic antibiotic administration. More localized approaches offer a number of advantages. The advantages of such antibiotic combinations include, but are not limited to, targeting a broader spectrum of microbes; faster microbial eradication; sparing the subject systemic exposure to the individual antimicrobial agents; enhancing the antimicrobial activity against microbes considered resistant to individual agents; and enhancing the antimicrobial activity against microbes considered resistant to individual agents at levels appropriate for systemic administration.
    Type: Grant
    Filed: January 26, 2015
    Date of Patent: June 16, 2020
    Inventor: Susanne Gardner
  • Patent number: 10682359
    Abstract: Compounds discovered through a high-throughput screen, along with methods of use of the compounds, are provided. The compounds can be used to strongly inhibit key drug targets found in protozoan parasites, e.g., the target Trypanosoma cruzi glucokinase. Compounds include derivatives of N-phenylbenzenesulfonamide, barbituric acid, (R)-3-(piperidin-2-yl)pyridine, 3-nitro-2-phenyl-2H-chromene, 6-amino-3-methyl-4-phenyl-1,4-dihydropryranole[2,3-c]pyrazole-5-carbonitrile, and gossypol (2,2?-Bis(formyl-1,6,7-trihydroxy-5-isopropyl-3-methylnaphthalene).
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: June 16, 2020
    Assignee: University of South Carolina
    Inventor: Edward L. D'Antonio
  • Patent number: 10668039
    Abstract: The present invention is directed to compositions and methods for treating Adenoid Cystic Carcinoma (ACC).
    Type: Grant
    Filed: September 1, 2017
    Date of Patent: June 2, 2020
    Assignee: THE CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Leonard I. Zon, Joseph Mandelbaum
  • Patent number: 10639316
    Abstract: Methods of treating patients suffering from or exhibiting symptoms of mental, behavioral, and/or cognitive disorders with azelastine or a pharmaceutically acceptable salt of azelastine is disclosed.
    Type: Grant
    Filed: May 30, 2019
    Date of Patent: May 5, 2020
    Assignee: LA PharmaTech Inc.
    Inventors: Jianmin Wang, Geping Cui
  • Patent number: 10639297
    Abstract: The disclosure relates to ophthalmic pharmaceutical compositions comprising pilocarpine or a pharmaceutically acceptable salt. Aspects of the disclosure further relate to uses and preparations of ophthalmic pharmaceutical compositions comprising pilocarpine or a pharmaceutically acceptable salt, for correcting presbyopia and other ocular conditions in a subject.
    Type: Grant
    Filed: July 10, 2018
    Date of Patent: May 5, 2020
    Assignee: Orasis Pharmaceuticals Ltd.
    Inventors: Claes Feinbaum, Franc Salamun, Sudhir Patel
  • Patent number: 10639314
    Abstract: Methods of treating patients suffering from or exhibiting symptoms of mental, behavioral, and/or cognitive disorders with azelastine or a pharmaceutically acceptable salt of azelastine is disclosed.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: May 5, 2020
    Assignee: LA PharmaTech Inc.
    Inventors: Jianmin Wang, Geping Cui
  • Patent number: 10639315
    Abstract: A pharmaceutical composition containing the therapeutically active ingredients of azelastine or a pharmaceutically acceptable salt of azelastine and donepezil or rivastigmine or galantamine or a pharmaceutically acceptable salt of thereof is disclosed. A method of using the pharmaceutical composition for treating patients suffering from mental, behavioral, cognitive disorders is also disclosed.
    Type: Grant
    Filed: May 21, 2019
    Date of Patent: May 5, 2020
    Assignee: LA PharmaTech Inc.
    Inventors: Jianmin Wang, Geping Cui
  • Patent number: 10639320
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating liver fibrosis or liver cirrhosis, and more specifically, to a pharmaceutical composition for preventing or treating liver fibrosis or liver cirrhosis comprising a gold-containing agent. The pharmaceutical composition of the present invention, by comprising the gold-containing agent as an active ingredient, not only promotes M2-type transformation of macrophages but also inhibits the activation of stellate cells due to the increase of TREM-2 expression, and is thus expected to be effectively used as a pharmaceutical composition, a food composition, etc., for preventing, treating, or ameliorating liver fibrosis or liver cirrhosis. Additionally, gold-containing agents, such as auranofin, sodium aurothiomalate, and aurothioglucose, have long been used for the treatment of a different disease (rheumatoid arthritis), and thus they have an advantage in that they are less likely to cause adverse effects.
    Type: Grant
    Filed: August 20, 2015
    Date of Patent: May 5, 2020
    Assignee: KOREA UNITED PHARM. INC.
    Inventors: Keon Wook Kang, Nayoun Kim, Kyung Rok Yoon
  • Patent number: 10624884
    Abstract: The present invention concerns the use of an H4 agonist molecule against histamin, enantiomers of (AMINO-7 TRIETHOXY-4,5,6 OXO-1 DIHYDRO-1,3 ISOBENZOFURANNYL-3)-1 METHOXY-8 METHYL-2 METHYLENEDIOXY-6,7 TETRAHYDRO-,2,3,4 ISOQUINOLINE or tritoqualine, for the treatment of idiopathic pulmonary fibrosis.
    Type: Grant
    Filed: May 2, 2019
    Date of Patent: April 21, 2020
    Assignee: H4 ORPHAN PHARMA
    Inventors: Gaëtan Terrasse, Catherine Bur
  • Patent number: 10624885
    Abstract: Disclosed is the synthesis procedure for benzazolo[3,2-a]quinolinium chloride salts and the inclusion of chloro-substituent, amino-substituent, and nitro-substituent resulting in several compounds. The compounds are further used as markers due to their fluorescent properties including in hypoxic environments. This disclosure further describes anti-cancer screening of two BQS, namely, 7-benzyl-3-aminobenzimidazo[3,2-a]quinolinium chloride (ABQ-48: NSC D-763307) and the corresponding 7-benzyl-3-nitrobenzimidazo[3,2-a]quinolinium chloride (NBQ 48: NSC D-763303).
    Type: Grant
    Filed: February 13, 2018
    Date of Patent: April 21, 2020
    Inventors: Osvaldo Cox, Beatriz Zayas
  • Patent number: 10617686
    Abstract: The invention provides stable liquid formulations containing naloxone, a pharmaceutically acceptable salt or a derivative thereof. The invention further provides methods for treating opioid dependence, opioid overdose, and congenital insensitivity to pain with anhidrosis by administering the liquid formulations of the present invention intranasally to a patient in need thereof. Further, the invention provides a method of treating opioid dependence, opioid overdose, and congenital insensitivity to pain with anhidrosis by administering intranasally the naloxone formulations of the present invention.
    Type: Grant
    Filed: May 22, 2017
    Date of Patent: April 14, 2020
    Assignee: HIKMA PHARMACEUTICALS USA INC.
    Inventors: Kiran Amancha, Shivani Chilampalli, Thrimoorthy Potta, Ningxin Yan, Venkat R. Goskonda, Eshwaran Narayanan
  • Patent number: 10617678
    Abstract: Described herein are methods for distributing temsirolimus to a tissue surrounding a blood vessel for treating vascular diseases. Also disclosed are injectable compositions of temsirolimus for delivery into the tissue surrounding a blood vessel for treating vascular diseases.
    Type: Grant
    Filed: February 7, 2018
    Date of Patent: April 14, 2020
    Assignee: MERCATOR MEDSYSTEMS, INC.
    Inventor: Kirk Patrick Seward
  • Patent number: 10611727
    Abstract: The present invention relates to 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives having pharmacological activity formula (I) to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy and/or prophylaxis of a cognitive disorder.
    Type: Grant
    Filed: September 26, 2018
    Date of Patent: April 7, 2020
    Assignees: UNIVERSITAT DE BARCELONA, FUNACIÓ INSTITUT DE RECERCA BIOMÉDICA, IPROTEOS S.L.
    Inventors: Ernest Giralt Lledó, Teresa Tarragó Clua, Roger Prades Cosano, Soledad Royo Gracia
  • Patent number: 10610522
    Abstract: The present invention provides new methods and kits for the retreatment of IBS.
    Type: Grant
    Filed: December 30, 2016
    Date of Patent: April 7, 2020
    Assignee: Salix Pharmaceuticals, Inc.
    Inventors: Pam Golden, Enoch Bortey, William Forbes, Craig Paterson
  • Patent number: 10610485
    Abstract: A Methotrexate composition for oral administration is provided comprising a pharmaceutically acceptable salt of Methotrexate and an aqueous carrier agent. The Methotrexate salt is substantially or completely soluble in the aqueous carrier agent, forming an aqueous solution. There is also provided a method of manufacturing a Methotrexate composition for oral administration, comprising mixing a pharmaceutically acceptable salt of Methotrexate with an aqueous carrier agent until the Methotrexate salt is substantially or completely soluble in the carrier agent to form an aqueous solution.
    Type: Grant
    Filed: February 4, 2019
    Date of Patent: April 7, 2020
    Assignee: Rosemont Pharmaceuticals Ltd
    Inventors: Carl Tierney, Stacey Powell, Peter Braybrooke, Geraint Jones
  • Patent number: 10610517
    Abstract: Disclosed herein are compositions and methods for treating neoplastic diseases. Included are compositions and methods that are effective against multiple myeloma cells resistant to conventional and bortezomib treatment. Furthermore, combination treatment with two different proteosome inhibitors is shown to be synergistic for treating multiple myeloma.
    Type: Grant
    Filed: March 25, 2014
    Date of Patent: April 7, 2020
    Assignees: Celgene International II SÀRL, Dana-Farber Cancer Institute, Inc.
    Inventors: Kenneth C. Anderson, Dharminder Chauhan, Michael A. Palladino
  • Patent number: 10588901
    Abstract: Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.
    Type: Grant
    Filed: May 3, 2018
    Date of Patent: March 17, 2020
    Assignee: Aerie Pharmaceuticals, Inc.
    Inventors: Casey Kopczynski, Cheng-Wen Lin, Jill Marie Sturdivant, Mitchell A. deLong
  • Patent number: 10588908
    Abstract: A method of treating a pediatric cancer in a subject in need thereof. The method includes administering to the subject a therapeutically effective amount of (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide, or a pharmaceutically acceptable salt thereof, or a combination thereof.
    Type: Grant
    Filed: January 3, 2018
    Date of Patent: March 17, 2020
    Assignee: Loxo Oncology, Inc.
    Inventors: Michael Cox, Nisha Nanda
  • Patent number: 10584113
    Abstract: The present technology is directed to compositions comprising d-threo-methylphenidate conjugates and unconjugated methylphenidate. The present technology also relates to compositions and oral formulations comprising d-threo-methylphenidate conjugated to nicotinoyl-L-serine, and/or a pharmaceutically acceptable salt thereof, and unconjugated methylphenidate and/or a pharmaceutically acceptable salt thereof. The present technology additionally relates to a pharmaceutical kit containing the composition comprising d-threo-methylphenidate conjugated to nicotinoyl-L-serine, and/or a pharmaceutically acceptable salt thereof, and unconjugated methylphenidate and/or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: June 4, 2019
    Date of Patent: March 10, 2020
    Assignee: KemPharm, Inc.
    Inventors: Travis Mickle, Sven Guenther, Guochen Chi